- Home
- GAME vs PSTV Comparison
GAME vs PSTV Comparison
Compare GAME & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- PSTV
- Stock Information
- Founded
- GAME 2011
- PSTV 1996
- Country
- GAME United States
- PSTV United States
- Employees
- GAME N/A
- PSTV N/A
- Industry
- GAME
- PSTV Medical/Dental Instruments
- Sector
- GAME
- PSTV Health Care
- Exchange
- GAME Nasdaq
- PSTV Nasdaq
- Market Cap
- GAME 68.2M
- PSTV 61.1M
- IPO Year
- GAME 2009
- PSTV N/A
- Fundamental
- Price
- GAME $0.47
- PSTV $0.46
- Analyst Decision
- GAME
- PSTV Strong Buy
- Analyst Count
- GAME 0
- PSTV 4
- Target Price
- GAME N/A
- PSTV $7.75
- AVG Volume (30 Days)
- GAME 1.8M
- PSTV 6.6M
- Earning Date
- GAME 11-13-2025
- PSTV 10-30-2025
- Dividend Yield
- GAME N/A
- PSTV N/A
- EPS Growth
- GAME N/A
- PSTV N/A
- EPS
- GAME N/A
- PSTV N/A
- Revenue
- GAME $102,810,388.00
- PSTV $5,258,000.00
- Revenue This Year
- GAME $2.32
- PSTV $9.91
- Revenue Next Year
- GAME $26.42
- PSTV $1.06
- P/E Ratio
- GAME N/A
- PSTV N/A
- Revenue Growth
- GAME 36.23
- PSTV N/A
- 52 Week Low
- GAME $0.44
- PSTV $0.16
- 52 Week High
- GAME $2.87
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- GAME 31.91
- PSTV 37.47
- Support Level
- GAME $0.44
- PSTV $0.50
- Resistance Level
- GAME $0.55
- PSTV $0.58
- Average True Range (ATR)
- GAME 0.05
- PSTV 0.05
- MACD
- GAME -0.01
- PSTV -0.01
- Stochastic Oscillator
- GAME 11.10
- PSTV 6.96
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).